Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

8.770
-0.330-3.63%
Volume:150.35M
Turnover:1.32B
Market Cap:101.05B
PE:22.10
High:9.090
Open:8.900
Low:8.705
Close:9.100
52wk High:10.720
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:1.39
T/O Rate:1.30%
Dividend:0.34
Dividend Rate:3.84%
EPS(LYR):0.397
ROE:20.90%
ROA:10.70%
PB:2.30
PE(LYR):22.10
PS:2.76

Loading ...

Movement Alert|CSPC PHARMA Rises 3.23% in Regular Trading, Therapeutic mRNA Vaccine Enters Phase II Clinical Trial

Market Focus
·
Jul 24

CSPC Pharma Starts Phase 2 Trial of HPV Therapeutic Vaccine in China

MT Newswires Live
·
Jul 23

CSPC Pharma Launches Phase II Trial of mRNA Vaccine SYS6026 for HPV16/18-Related Cervical HSIL

Bulletin Express
·
Jul 22

CSPC Pharmaceutical Group Stock Slips 1.1% in Hong Kong

Dow Jones
·
Jul 21

CSPC Pharmaceutical Group Stock Rallies 4.9% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 20

Movement Alert|CSPC Pharmaceutical Rises 3.21% in Regular Trading, First ADC Drug Application Accepted Amid Sector Recovery

Market Focus
·
Jul 20

CSPC Pharma's Application for Breast Cancer Drug Candidate Accepted in China

MT Newswires Live
·
Jul 17

CSPC Pharmaceutical’s Trastuzumab Envedotin NDA Accepted by China’s NMPA

Bulletin Express
·
Jul 17

CSPC Pharma's New Drug Application for Envituzumab Injection Accepted by Chinese Regulator

Stock News
·
Jul 17

CSPC Pharmaceutical - Nmpa Accepts New Drug Application for Trastuzumab Envedotin Injection

THOMSON REUTERS
·
Jul 17

CSPC Pharmaceutical - Product Indicated for Unresectable or Metastatic Her2-positive Breast Cancer in Adults

THOMSON REUTERS
·
Jul 17

Movement Alert|CSPC Pharmaceutical Falls 3.02% in Regular Trading, Trading at HKD 8.22

Market Focus
·
Jul 17

CSPC Pharma Begins Two Drug Trials in China

MT Newswires Live
·
Jul 16

CSPC PHARMA Initiates Phase II Trial in China for Novel Sirolimus Formulation in Rare Vascular Tumor

Stock News
·
Jul 16

CSPC PHARMA's Phase III Trial for SYS 6043 in Platinum-Resistant Gynecologic Cancers Commences at First Chinese Site

Stock News
·
Jul 16

CSPC Pharmaceutical Initiates China Phase II Trial of Albumin-bound Sirolimus Injection for Epithelioid Haemangioendothelioma

Reuters
·
Jul 16

CSPC Pharmaceutical Initiates China Phase III Trial of Sys6043 in Platinum-resistant Ovarian Cancer

Reuters
·
Jul 16

CSPC Pharmaceutical Group Stock Rallies 2.0% in Hong Kong

Dow Jones
·
Jul 16

Movement Alert|CSPC Pharmaceutical Rises 3.08% in Regular Trading, Breast Cancer Drug Combo Granted Breakthrough Designation Amid Institutional Accumulation

Market Focus
·
Jul 16

CSPC Pharmaceutical Group Stock Rises 3.9% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 15